Genomic correlates of clinical benefits from atezolizumab combined with bevacizumab vs. atezolizumab alone in patients with advanced hepatocellular carcinoma (HCC)

被引：23
|
作者：
Zhu, Andrew X. [1 ,2 ]
Guan, Yinghui [3 ]
Abbas, Alexander R. [3 ]
Koeppen, Hartmut [3 ]
Lu, Shan [3 ]
Hsu, Chih-Hung [4 ]
Lee, Kyung-Hun [5 ]
Lee, Michael S. [6 ]
He, Aiwu Ruth [7 ]
Mahipal, Amit [8 ]
Ding, Beiying [3 ]
Spahn, Jessica [3 ]
Verret, Wendy [3 ]
Ryoo, Baek-Yeol [9 ]
Wang, Yulei [3 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Jiahui Int Canc Ctr, Boston, MA USA
[3] Genentech Inc, San Francisco, CA 94080 USA
[4] Natl Taiwan Univ Hosp, Taipei, Taiwan
[5] Seoul Natl Univ, Seoul, South Korea
[6] UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[7] Georgetown Univ, Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[8] Mayo Clin, Rochester, MN USA
[9] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-CT044
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT044
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Prediction for gastrointestinal bleeding in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
    Park, Kanghee
    Kim, Euichang
    Yang, Ji Won
    Choi, Won-Mook
    Lee, Danbi
    Shim, Ju Hyun
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    Choi, Jonggi
    JOURNAL OF HEPATOLOGY, 2023, 78 : S573 - S573
  • [42] The efficacy of molecular targeted therapies after atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC) in Japan
    Tsuchiya, Kaoru
    Hayakawa, Yuka
    Yasui, Yutaka
    Kakegawa, Tatsuya
    Higuchi, Mayu
    Takaura, Kenta
    Tanaka, Shohei
    Maeyashiki, Chiaki
    Kaneko, Shun
    Tamaki, Nobuharu
    Nakanishi, Hiroyuki
    Kurosaki, Masayuki
    Izumi, Namiki
    JOURNAL OF HEPATOLOGY, 2022, 77 : S379 - S379
  • [43] Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice
    Jain, Ankit
    Chitturi, Shivakumar
    Peters, Geoffrey
    Yip, Desmond
    WORLD JOURNAL OF HEPATOLOGY, 2021, 13 (09) : 1132 - 1142
  • [44] A phase I clinical trial of stereotactic body radiotherapy with atezolizumab and bevacizumab in advanced hepatocellular carcinoma.
    Brown, Timothy J.
    Minn, Andy J.
    Carpenter, Erica L.
    Ben-Josef, Edgar
    Karasic, Thomas Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS626 - TPS626
  • [45] Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
    McDermott, David F.
    Huseni, Mahrukh A.
    Atkins, Michael B.
    Motzer, Robert J.
    Rini, Brian I.
    Escudier, Bernard
    Fong, Lawrence
    Joseph, Richard W.
    Pal, Sumanta K.
    Reeves, James A.
    Sznol, Mario
    Hainsworth, John
    Rathmell, W. Kimryn
    Stadler, Walter M.
    Hutson, Thomas
    Gore, Martin E.
    Ravaud, Alain
    Bracarda, Sergio
    Suarez, Cristina
    Danielli, Riccardo
    Gruenwald, Viktor
    Choueiri, Toni K.
    Nickles, Dorothee
    Jhunjhunwala, Suchit
    Piault-Louis, Elisabeth
    Thobhani, Alpa
    Qiu, Jiaheng
    Chen, Daniel S.
    Hegde, Priti S.
    Schiff, Christina
    Fine, Gregg D.
    Powles, Thomas
    NATURE MEDICINE, 2018, 24 (06) : 749 - +
  • [46] ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): REAL-WORLD EXPERIENCE FROM A US COMMUNITY ONCOLOGY NETWORK
    Cosgrove, David
    Tan, Amie
    Hernandez, Sairy
    Mahrus, Sami
    Osterland, Andrew
    Murphy, John
    Loaiza-Bonilla, Arturo
    HEPATOLOGY, 2022, 76 : S1308 - S1309
  • [47] Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
    David F. McDermott
    Mahrukh A. Huseni
    Michael B. Atkins
    Robert J. Motzer
    Brian I. Rini
    Bernard Escudier
    Lawrence Fong
    Richard W. Joseph
    Sumanta K. Pal
    James A. Reeves
    Mario Sznol
    John Hainsworth
    W. Kimryn Rathmell
    Walter M. Stadler
    Thomas Hutson
    Martin E. Gore
    Alain Ravaud
    Sergio Bracarda
    Cristina Suárez
    Riccardo Danielli
    Viktor Gruenwald
    Toni K. Choueiri
    Dorothee Nickles
    Suchit Jhunjhunwala
    Elisabeth Piault-Louis
    Alpa Thobhani
    Jiaheng Qiu
    Daniel S. Chen
    Priti S. Hegde
    Christina Schiff
    Gregg D. Fine
    Thomas Powles
    Nature Medicine, 2018, 24 : 749 - 757
  • [48] Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice
    Ankit Jain
    Shivakumar Chitturi
    Geoffrey Peters
    Desmond Yip
    World Journal of Hepatology, 2021, 13 (09) : 1132 - 1142
  • [49] Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice
    Nakagawa, Miyuki
    Inoue, Masanori
    Ogasawara, Sadahisa
    Maruta, Susumu
    Okubo, Tomomi
    Itokawa, Norio
    Iino, Yotaro
    Obu, Masamichi
    Haga, Yuki
    Seki, Atsuyoshi
    Kikuchi, Yasuharu
    Kogure, Tadayoshi
    Yumita, Sae
    Ishino, Takamasa
    Ogawa, Keita
    Fujiwara, Kisako
    Iwanaga, Terunao
    Fujita, Naoto
    Sakuma, Takafumi
    Kojima, Ryuta
    Kanzaki, Hiroaki
    Koroki, Keisuke
    Taida, Takashi
    Kobayashi, Kazufumi
    Kiyono, Soichiro
    Nakamura, Masato
    Kanogawa, Naoya
    Kondo, Takayuki
    Nakagawa, Ryo
    Nakamoto, Shingo
    Muroyama, Ryosuke
    Chiba, Tetsuhiro
    Itobayashi, Ei
    Atsukawa, Masanori
    Koma, Yoshihiro
    Azemoto, Ryosaku
    Ito, Kenji
    Mizumoto, Hideaki
    Shinozaki, Masami
    Kato, Jun
    Kato, Naoya
    CANCER, 2023, 129 (04) : 590 - 599
  • [50] Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma
    Zhang, Xin
    Wang, Jingjing
    Shi, Juanjuan
    Jia, Xiaoli
    Dang, Shuangsuo
    Wang, Wenjun
    JAMA NETWORK OPEN, 2021, 4 (04)
12345